13 episodes
Patient Pulse Thomas Nero, MD
-
- Health & Fitness
-
-
5.0 • 1 Rating
-
At Patient Pulse (formerly Patients First), we aim to improve understanding of difficult topics in cardiology and medicine. Easy enough for the layman, but detailed enough for someone who wants to know more about their condition or that of a loved one. Also available on Apple Podcasts, Google Podcasts and most other services. Subscribe to have new podcasts sent directly to your player.
-
African American Heart Study with Dr Elizabeth Ofili and Iyana Liburd
Dr. Ofili and Iyana discuss their experience with the African American Heart Study and why it is so important to be involved.
-
Blood Thinners in Atrial Fibrillaiton and Coronary Atery Disease with Dr.Michael Gibson
Dr Gibson from Harvard's Baim Institue discusses anticoagulants for atrial fibrillation and coronary artery disease with Dr. Thomas Nero. The also discuss the concern about bleeding with current medical therapy and future options for patients.
-
Weight Loss and CV Outcomes with Ozempic, Munjaro and Similar Drugs with Dr. Peter Toth
Dr Peter Toth discusses with Dr. Thomas Nero the new classes of diabetes medications, SGLT2 inhibitors (eg Jardiance) and GLP1 receptor agonists (eg Ozempic and Munjaro.) These drugs have been in the news due to an impressive effect on weight reduction, but they also improve cardiovascular outcomes in diabetic and non-diabetic patients.
-
Reducing Heart Attack Risk with Dr. Peter Toth
In this brief discussion, Dr. Toth discusses the current recommendations on decreasing cardiovascular risk and where we are headed to decrease your risk of a heart attack.
-
Inflammation, Coronary Artery Disease and hs-CRP with Dr Paul Ridker
Coronary inflammation is the final pathway for the development of coronary artery disease. Dr. Paul Ridker discusses the role of inflammation, hs-CRP and therapies with Dr. Thomas Nero.
-
Evolve MI and Pragmatic Clinical Trials with Dr. Christopher Cannon
Dr Christopher Cannon discusses the EVOLVE-MI trial to decrease cholesterol with Evolocumab early after Myocardial Infarction as well as the rational for a less intensive way to study patients with open label, pragmatic clinical trials.